Form 4: OrbiMed Advisors Sells Enliven Therapeutics Shares

OrbiMed Advisors LLC reported the sale of 281,408 shares of Enliven Therapeutics, Inc. common stock at a price of $45.02 per share.

Summary

• OrbiMed Advisors LLC, a 10% owner of Enliven Therapeutics, Inc. (ELVN), executed the sale of 281,408 shares of common stock.
• The transaction occurred on June 15, 2026, at a price of $45.02 per share.
• The shares were held by two entities: OrbiMed Genesis Master Fund, L.P. (9,086 shares) and OrbiMed Private Investments VII, LP (272,322 shares).
• Following these transactions, the reporting entities maintain a significant beneficial ownership stake in the company.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; it is a routine regulatory disclosure of a secondary market transaction by a major shareholder rather than a fundamental change in company operations.

Positives

• The transaction reflects liquidity events for major institutional investors, which is standard practice for venture capital and private equity firms managing fund lifecycles.

Negatives

• The sale of a significant block of shares by a 10% owner may be perceived by some market participants as a reduction in long-term conviction or a signal of profit-taking.

Risks

• Future sales by major institutional shareholders could exert downward pressure on the stock price.
• Market perception of insider or major shareholder selling can lead to increased volatility.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this ownership disclosure.

Industry Context

StockSavvy.ai notes that institutional divestment in the biotechnology sector is common as funds reach maturity or rebalance portfolios, and does not necessarily reflect a change in the underlying fundamentals of the issuer.

Comparison to Industry Standards

• The filing follows standard SEC disclosure requirements for 10% beneficial owners.
• Institutional selling of this nature is consistent with typical exit strategies for life sciences venture capital firms.

Stakeholder Impact

• Shareholders may experience short-term price volatility due to the volume of shares sold by a major institutional holder.

Next Steps

• Continued monitoring of future Form 4 filings to track further changes in institutional ownership.

Key Dates

Keywords

Enliven Therapeutics, ELVN, OrbiMed, Insider Trading, Form 4, Beneficial Ownership, Biotech